Advanced molecular therapies for neurological diseases: focus on stroke, alzheimer's disease, and parkinson's disease

Simple item page
dc.contributor.authorKatta, Madhumitha
dc.contributor.authorMathew, Blessy Aksa
dc.contributor.authorChaturvedi, Pragya
dc.contributor.authorLudhiadch, Abhilash
dc.contributor.authorMunshi, Anjana
dc.date.accessioned2024-01-21T10:54:08Z
dc.date.accessioned2024-08-14T07:40:52Z
dc.date.available2024-01-21T10:54:08Z
dc.date.available2024-08-14T07:40:52Z
dc.date.issued2022-09-06T00:00:00
dc.description.abstractNeurological diseases (NDs) are one of the leading causes of disability and the second leading cause of death globally. Among these stroke, Alzheimer's disease (AD), and Parkinson's disease (PD) are the most common NDs. A rise in the absolute number of individuals affected with these diseases indicates that the current treatment strategies in management and prevention of these debilitating diseases are not effective sufficiently. Therefore, novel treatment strategies are being explored to cure these diseases by addressing the causative mechanisms at the molecular level. Advanced therapies like gene therapy (gene editing and gene silencing) and stem cell therapies aim to cure diseases by gene editing, gene silencing and tissue regeneration, respectively. Gene editing results in the deletion of the aberrant gene or insertion of the corrected gene which can be executed using the CRISPR/Cas gene editing tool a promising treatment strategy being explored for many other prevalent diseases. Gene silencing using siRNA silences the gene by inhibiting protein translation, thereby silencing its expression. Stem cell therapy aims to regenerate damaged cells or tissues because of their ability to divide into any type of cell in the human body. Among these approaches, gene editing and gene silencing have currently been applied in vitro and to animal models, while stem cell therapy has reached the clinical trial stage for the treatment of NDs. The current status of these strategies suggests a promising outcome in their clinical translation. � 2022, Fondazione Societ� Italiana di Neurologia.en_US
dc.identifier.doi10.1007/s10072-022-06356-6
dc.identifier.issn15901874
dc.identifier.urihttp://10.2.3.109/handle/32116/4222
dc.identifier.urlhttps://link.springer.com/10.1007/s10072-022-06356-6
dc.language.isoen_USen_US
dc.publisherSpringer-Verlag Italia s.r.l.en_US
dc.subjectCRISPR/Casen_US
dc.subjectGene editingen_US
dc.subjectNeurological diseasesen_US
dc.subjectsiRNAen_US
dc.subjectStem Cell Therapyen_US
dc.titleAdvanced molecular therapies for neurological diseases: focus on stroke, alzheimer's disease, and parkinson's diseaseen_US
dc.title.journalNeurological Sciencesen_US
dc.typeReviewen_US
dc.type.accesstypeClosed Accessen_US

Files

Collections

Human Genetics And Molecular Medicine - Research Publications